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oCancer cells induce immunologic tolerance  absence of an immune response against certain antigens, causing the escape of these cells from the immune system. 
o 2 groups of tumor antigens: true tumor-specific antigens (encoded by mutant cellular genes), and tumor-associated antigens (encoded by normal cellular genes). 
Figure 1. 
Immunosuppressive 
strategies. (1) 
impairment of the Ag 
presentation/processin
g machinery, (2) 
defects in TCR proximal 
signals, (3) secretion of 
immunoregulatory 
cytokines, (4) negative 
costimulatory signals,  
(5) tryptophan 
depletion, (6) 
proapoptotic pathways, 
and (7) regulatory T-
cells. Adapted from 
reference [2]. 
 
 Programmed cell death-1 is a 288 aa protein that belongs to Ig superfamily.  
     Consists in an extracellular IgV-like domain, and a cytoplasmic region  
    (with an ITIM and an ITSM). ― regulator of T-cell function (figure 2). 
 Ligands: PD-L1 (B7-H1) and PD-L2 (B7-DC), expressed in lymphoid, in  
     non-lymphoid cells and in tumor cells. 
 
Figure 2. Human 
programmed 
cell death 1 
receptor 
structure. 
Reference [8]. 
Apoptosis, anergy, exhaustion, molecular 
shield, IL-10 production  T-cell tolerance 
Figure 3. PD-1 signaling. (1)  T-cell 
activation, (2) PD-1 expression, 
(3) PD-1/PD-L interaction, (4) 
ITSM phosphorylation, (5) SHP-2 
recruitment and phosphorylation, 
(6+7) dephosphorylation of 
proximal and downstream 
effector molecules. Adapted 
from reference [10]. 
PD-1 signaling 
*It have been observed 
in PD-1 KO mice the loss 
of peripheral tolerance 
and the development of 
autoimmunity.  
 
 CTLA-4 (Cytotoxic T-lymphocyte associated antigen protein 4), is  
     a 223 aa glycoprotein that belongs to Ig superfamily and has an  
     extracellular IgV-like domain. ― regulator  of T-cell activation  
     (figure 4). 
 Ligands: B7-1 (CD80) and B7-2 (CD86), expressed in APCs and in tumor cells. 
 
Figure 4. Solution 
structure of human 
CTLA-4 with a 
tetrasaccharide core 
attached. Reference 
[26]. 
Prevention of T-cell activation through 
proximal and distal mechanisms  
Figure 5. Activated CTLA-4 binds to: 
(1) SHP1/2  PI3K dephosphorylation, 
(2)  PP2A  ↓ Akt phosphorylation, 
and (3)  TCR-CD3 complex  no 
phosphorylation  no Zap70, Syk and 
Fyn binding. 
*CTLA-4 KO mice developed 
autoimmune diseases and 
died at 3-4 weeks old  
significant role in the 
development of peripheral 
tolerance to self-proteins. 
CTLA-4 signaling 
CTLA-4 PATHWAY PD-1 PATHWAY 
Figure 6. T-
lymphocyte 
inhibition  by 
CTLA-4 and PD-
1. CTLA-4 
preserves some 
PI3K activity but 
inhibits Akt 
directly. PD-1: 
inhibits PI3K 
directly. Adapted 
from reference 
[35]. 
CTLA-4 PD-1 Implications 
Expression T-cells 
T-cells, B-cells 
and myeloid cells 
PD-1: more broadly role in the regulation of immune responses 
Interaction with AP2 
(endocytosis) 
Yes No 
CTLA-4 undetectable on the cell surface; PD-1 greater 
expression 
SHP-2 association Indirectly Directly 
CTLA-4 preserves a little PI3K activity, whereas PD-1 affects a 
more global inhibition of T-lymphocytes (figure 6) 
DIFFERENCES BETWEEN PD-1 AND CTLA-4 
 
A variety of checkpoint blocking agents have been developed to block PD-1 and 
CTLA-4 signaling (including monoclonal Ab). Examples: Nivolumab and 
Lambrolizumab (anti-PD-1), Ipilimumab (anti-CTLA-4). 
 
IMPLICATIONS FOR CANCER IMMUNOTHERAPY 
INTRODUCTION 
PROS 
 More effective than classical 
therapies in metastatic cancers. 
 Synergistic activity  combinatorial 
therapies. 
CONS 
 Side effects. 
 Very new, we don’t know the long-
term side effects. 
 Currently very expensive therapies  
not accessible to everyone. 
PD-1 and CTLA-4: powerful 
negative regulators of the 
immune response (KO 
experiments, development 
of autoimmunity)  very 
important role in the 
regulation of the IS, 
immunosuppression. 
1 2 
Therapy: it’s difficult to 
find a monotherapy that 
works at 100% because 
there are many different 
molecules and 
mechanisms involved,  
combinatorial therapies 
should be tested. 
Cancer uses this 
mechanism to evade 
and escape from IS 
cells  tolerance 
toward cancer cells, 
leading to the 
development of 
malignant tumors. 
CONCLUDING REMARKS 
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Downregulation of the Ag presentation machinery 
Absence/↓ MHC-I expression and changes in the spectrum of 
peptides presented by MHC-I 
Defects in proximal TCR-mediated signaling 
↓ expression of CD3ζ chain, p56lck and p59fyn in lymphocytes 
Secretion of immunoregulatory cytokines  
TGFβ, IL-10, prostaglandin E2 and sialomucins 
Negative costimulatory pathways 
CTLA-4 and PD-1 
Modulation of tryptophan catabolism 
Indoleamine 2,3-dioxygenase overexpressed by  
tumor cells  tryptophan depletion 
“Tumor counterattack hypothesis” 
Death signals to T-cells through FasL/TRAIL-dependent 
mechanism 
Regulatory T-cells 
Under the influence of CCL22 Tregs migrate into tumor site 
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